



Docket No.: 28110/37665

1647
RECEIVED
JUL 17 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Ford, et al.
Serial No:	09/981,649 09/981649
Filed:	October 15, 2001
For:	EGF MOTIF PROTEIN, EGFL6, MATERIALS AND METHODS
Examiner:	Bridget E. Bunner
Art Unit:	1647

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, with sufficient postage as first class mail in an envelope addressed to Mail Stop INFORMATION DISCLOSURE STATEMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: July 10, 2003

Name of Person Mailing: Donna B. Rose

Donna B. Rose
Signature of Person Mailing

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop INFORMATION DISCLOSURE STATEMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by Applicants in connection with the above-identified application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents A1-A2, B1-B5 and C1-C16 cited on the PTO-1449 are not provided because they were previously submitted to the U.S. Patent and Trademark Office in parent applications, U.S. Serial No. 09/363,316 filed July 28, 1999 and U.S. Serial No. 09/981,649 filed October 15, 2001, from which priority is claimed under 35 U.S.C. §120. However, copies of these documents will be resubmitted at the Examiner's request. Copies of documents B6 and C17-C19 are submitted herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. § 102 or § 103.

In accordance with 37 C.F.R. §1.98(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted before the mailing of a first Office Action on the merits. However, the Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169.

Respectfully submitted,

Date: July 10, 2003

By: Renée S. Polizotto
Renée S. Polizotto, Ph.D
Agent for Applicant
Registration. No. 53,474
NUVELO, Inc. (formerly HYSEQ, Inc.)
675 Almanor Avenue
Sunnyvale, CA 94085
(408) 215-4522
(408) 524-8145 (Telefacsimile)

JUL 15 2003

SHEET 1 of 2

Form PTO-1449 (Modified)

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.
28110/37665Serial No.
09/981,649Applicant(s)
Ford et al.Filing Date
10/15/2001Art Unit
1647

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
A1	5,194,596	3/16/93	Tisher et al.	530	399	
A2	09/233,546	12/30/98	D. Holzman			12/30/98

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
B1	WO 92/19734	11/12/92	PCT		
B2	WO 99/06553	02/11/99	PCT		
B3	WO 99/46281	09/16/99	PCT		
B4	WO 00/37638	06/29/00	PCT		
B5	WO 00/39284	07/06/00	PCT		
B6 *	WO 99/27096	06/03/99	PCT		

OTHER DOCUMENTS

C1	McKnight <i>et al.</i> , EGF-TM7: a novel subfamily of seven-transmembrane-region leukocyte cell-surface molecules, Immunology Today; 17(6): 283-287 (June 1996).
C2	Genebank Accession No.: R99817, yq69bll.rl Soares fetal liver spleen 1NFLS <i>Homo sapiens</i> cDNA clone IMAGE: 201021 5' similar to SP:FBN1 HUMAN P35555 FIBRILLIN 1, mRNA sequence, deposited by Hillier <i>et al.</i> , dated 14 September 1995.
C3	Genebank Accession No.: AA025649, ze85d03.rl Soares fetal heart NbHH19W <i>Homo sapiens</i> cDNA clone IMAGE: 365765 5', mRNA sequence, deposited by Hillier <i>et al.</i> , dated 14 August 1996.
C4	Genebank Accession No.: AA 436507, zv08c07.rl Soares NhHMPu_S1 <i>Homo sapiens</i> cDNA clone IMAGE: 753036 5', mRNA sequence, deposited by Hillier <i>et al.</i> , dated 30 May 1997.

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified)

JUL 15 2003

Atty. Docket No.
28110/37665Serial No.
09/981,649

INFORMATION DISCLOSURE STATEMENT

Applicant(s)
Ford et al.Filing Date
10/15/2001Art Unit
1642

C5	Cunningham & Wells, High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis, Science 244: 1081-1085 (June 2, 1989).
C6	Selander <i>et al.</i> H NMR Assignment and Secondary Structure of the Ca ²⁺ -Free Form of the Amino-Terminal Epidermal Growth Factor like Domain in Coagulation Factor X, Biochemistry 29: 8111-8118 (1990).
C7	Graves <i>et al.</i> , Insight into E-selection/ligand Interaction from the Crystal Structure and Mutagenesis of the Iec/EGF Domains, Nature 367: 532-538 (February 10, 1994).
C8 * ↓	Davis, The Many Faces of Epidermal Growth Factor Repeats, The New Biologist 2(5): 410-419 (May 1990).
C9	Connelly & Hegele, Hepatic Lipase Deficiency, Clin. Reviews in Clin. Lab. Sciences 35(6): 547-572 (1998).
C10	Guadiz <i>et al.</i> , Thrombin Cleavage-Independent Deposition of Fibrinogen in Extracellular Matrices, Blood 90(7): 2644-2653 (October 1, 1997).
C11	Boukerche <i>et al.</i> , Thrombospondin Modulates Melanoma - Platelet Interactions and Melanoma Tumour Cell Growth <i>in vivo</i> , British Journal of Cancer 72: 108-116 (1995).
C12	West <i>et al.</i> , Correlation of Vascular Endothelial Growth Factor Expression with Fibroblast Growth Factor-8 Expression and Clinico-Pathologic Parameters in Human Prostate Cancer, British Journal of Cancer 85(4): 576-583 (2001).
C13	Riedel <i>et al.</i> , Immunocytochemical Localization of Basic Fibroblast Growth Factor in Squamous Cell Carcinomas of the Head and Neck, Anticancer Research 27: 1873-1878 (2001).
C14	Chan <i>et al.</i> , Prostate-Specific Antigen as a Marker for Prostatic Cancer: a Monoclonal and a Polyclonal Immunoassay Compared, Clinical Chemistry 33(10): 1916-1920 (1987).
C15	Hayes <i>et al.</i> , Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662, Clinical Cancer Research Vol. 7: 2703-2711 (September 2001).
C16	Lissoni <i>et al.</i> , The Biological Significance of Soluble Interleukin-2 Receptors in Solid Tumors, Eur J. Cancer 26(1): 33-36 (1990).
C17	Buchner <i>et al.</i> , Identification of a New EGF-Repeat-Containing Gene from Human Xp22: A Candidate for Developmental Disorders, Genomics 65:16-23 (2000).
C18	Yeung <i>et al.</i> , Cloning of a Novel Epidermal Growth Factor Repeat containing Gene EGFL6: Expressed in Tumor and Fetal Tissues, Genomics 62:304-307 (1999).
C19	Invitation to Pay Additional Fees with Communication Relating to the Results of the Partial International Search for PCT/US01/32257, mailed November 15, 2002.

EXAMINER:

DATE CONSIDERED: